Cost effectiveness of recombinant activated factor VII for the control of bleeding in patients with severe blunt trauma injuries in the United Kingdom

Anaesthesia

Volumn 62, Issue 1, 2007, Pages 43-52

  Morris, S ^a   Ridley, Saxon ^b   Munro, V ^c   Christensen, M C ^d  

^a BRUNEL UNIVERSITY   (United Kingdom)

^b GLAN CLWYD HOSPITAL   (United Kingdom)

^c Novo Nordisk Ltd   (United Kingdom)

^d NOVO NORDISK A S   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

FRESH FROZEN PLASMA; PLACEBO; RECOMBINANT BLOOD CLOTTING FACTOR 7A;

ADULT; ARTICLE; BLEEDING; BLUNT TRAUMA; CLINICAL TRIAL; COHORT ANALYSIS; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COST BENEFIT ANALYSIS; COST EFFECTIVENESS ANALYSIS; COST OF ILLNESS; ERYTHROCYTE TRANSFUSION; FEMALE; HEALTH CARE COST; HEALTH CARE UTILIZATION; HUMAN; LIFESPAN; MAJOR CLINICAL STUDY; MALE; PHASE 2 CLINICAL TRIAL; QUALITY ADJUSTED LIFE YEAR; RANDOMIZED CONTROLLED TRIAL; SENSITIVITY ANALYSIS; TREATMENT OUTCOME; UNITED KINGDOM;

ADULT; CLINICAL TRIALS, PHASE II; COHORT STUDIES; COST-BENEFIT ANALYSIS; FACTOR VII; FEMALE; GREAT BRITAIN; HEALTH CARE COSTS; HEMORRHAGE; HUMANS; MALE; MODELS, ECONOMIC; QUALITY-ADJUSTED LIFE YEARS; RANDOMIZED CONTROLLED TRIALS; RECOMBINANT PROTEINS; STATE MEDICINE; SURVIVAL ANALYSIS; WOUNDS, NONPENETRATING;

EID: 33845311516     PISSN: 00032409     EISSN: 13652044     Source Type: Journal    
DOI: 10.1111/j.1365-2044.2006.04896.x     Document Type: Article

References (38)

1. Murray CL, Lopez AD. Mortality by cause for eight regions of the world. Global Burden of Disease Study. Lancet 1997; 349: 1269-76.
2. Sauaia A, Moore FA, Moore EE, et al. Epidemiology of trauma deaths: A reassessment. Journal of Trauma 1995; 38: 185-93.
3. Boffard KD, Riou B, Warren B, et al. Recombinant Factor VIIa as adjunctive therapy for bleeding control in severely injured trauma patients: Two parallel randomized, placebo-controlled, double-blind clinical trials. Journal of Trauma 2005; 59: 8-18.
4. NICE. Guidance to the Methods of Technology Appraisal. London: NICE, 2004.
5. TARN. http://www.tarn.ac.uk [accessed 6 February 2006].
6. Wright JC, Plenderleith L, Ridley SA. Long term survival following intensive care: Subgroup analysis and comparison with the general population. Anaesthesia 2003; 58: 637-42.
7. Government Actuary's Department. Interim life tables. http://www.gad.gov.uk/Life_Tables/Interim_life_tables.htm [accessed 30 August 2006].
8. Como JJ, Dutton RP, Scalea TM, et al. Blood transfusion rates in the care of acute trauma. Transfusion 2004; 44: 809-13.
9. Sauaia A, Moore FA, Moore EE, et al. Early predictors of postinjury multiple organ failure. Archives of Surgery 1994; 129: 39-45.
10. Moore FA, Moore EE, Sauaia A. Blood-transfusion: An independent risk factor for postinjury multiple organ failure. Archives of Surgery 1997; 132: 620-5.
11. Alcorn K, Aggarwal A. Single institution experience of recombinant activated factor VII (NovoSeven) in the management of intractable bleeding in surgical and trauma patients. Blood 2002; 100: Abstract no. 3840.
12. Aggarwal A, Catlett J, Alcorn K. Use of recombinant activated factor VII (rFVIIa) in the management of intractable bleeding in surgical and trauma patients. Blood 2001; 98: Abstract no. 3883.
13. Becton D, Saylors R, Morris J, et al. Treatment of bleeding with rFVIIa (NovoSeven ®) in four diverse cases. Blood 2001; 98: Abstract no. 1104.
14. Clark AD, Gordon WC, Walker ID, et al. 'Last-ditch'use of recombinant factor VIIa in patients with massive haemorrhage is ineffective. Vox Sanguinis 2004; 86: 120-4.
15. Dutton RP, McCunn M, Hyder M, et al. Factor VIIa for correction of traumatic coagulopathy. Journal of Trauma 2004; 57: 709-19.
16. Kamphuisen PW, van den Akker JM, Kaasjager KAH, et al. Control of life-threatening pulmonary bleeding with activated recombinant factor VII. American Journal of Medicine 2002; 112: 332-3.
17. Kenet G, Walden R, Eldad A, et al. Treatment of traumatic bleeding with recombinant factor VIIa. Lancet 1999; 354: 1879.
18. Kulkarni R, Daneshmand A, Guertin S, et al. Successful use of activated recombinant factor VII in traumatic liver injuries in children. Journal of Trauma 2004; 56: 1348-52.
19. Dincer AP, Abu-Hajir M, Christians KK, et al. Human recombinant activated factor seven, NovoSeven (rVIIa), in the management of massive bleeding despite adequate resuscitation in major trauma. Blood 2002; 100: Abstract no. 3918.
20. Morenski JD, Tobias JD, Jimenez DF. Recombinant activated factor VII for cerebral injury-induced coagulopathy in paediatric patients. Journal of Neurosurgery 2003; 98: 611-6.
21. O'Neill PA, Bluth M, Gloster ES, et al. Successful use of recombinant activated factor VII for trauma-associated hemorrhage in a patient without preexisting coagulopathy. Journal of Trauma 2002; 52: 400-5.
22. Siegel LJ, Gerigk L, Tuettenberg J, et.al. Cerebral sinus thrombosis in a trauma patient after recombinant activated factor VII infusion. Anesthesiology 2004; 100: 441-3.
23. Riou B, Landais P, Vivien B, et al. Distribution of the probability of survival is a strategic issue for randomized trials in critically ill patients. Anesthesiology 2001; 95: 56-63.
24. Niskanen M, Kari A, Halonen P. Five-year survival after intensive care: comparison of 12,180 patients with the general population. Critical Care Medicine 1996; 24: 1962-7.
25. Seguin J, Garber B, Coyle D, et al. An economic evaluation of trauma care in a Canadian lead trauma hospital. Journal of Trauma 1999; 47 (Suppl.): S99-S103.
26. National. Blood Service. Impact of cost pressures, developments and cost reduction programmes. Appendix 2 Draft National prices 2006/2007. London: National Blood Service, 2005.
27. Department of Health. NHS Reference Costs 2004. London: Department of Health, 2005.
28. Yuen P. OHE Compendium of Health Statistics, 17th edn. London: OHE, 2006.
29. Southampton Health Technology Assessments Centre. The Clinical and Cost-Effectiveness of Drotrecogin Alfa (Activated) (Xigris ™) for the Treatment of Severe Sepsis in Adults: A Systematic Review and Economic Evaluation (Excluding Commercial in Confidence Data). Technology assessment report commissioned by the HTA Programme on behalf of the National Institute for Clinical Excellence. London: NICE, 2003.
30. Curtis L, Netten A. Unit Costs of Health and Social Care, 2005. Kent: PSSRU, 2005.
31. Szende A, Williams A, eds. Measuring Self-Reported Population Health: An International Perspective Based on EQ-5d. Rotterdam: EuroQol group, 2004.
32. Lothgren M, Zethraeus N. Definition, interpretation and calculation of cost-effectiveness acceptability curves. Health Economics 2000; 9: 623-30.
33. Devlin N, Parkin D. Does NICE have a cost-effectiveness threshold and what other factors influence its decisions? A binary choice analysis. Health Economics 2004; 13: 437-52.
34. Towse A. What Is NICE's Threshold? An External View. In: Devlin N, Towse A, eds. Cost Effectiveness Thresholds: Economic and Ethical Issues. London: King's Fund/Office for Health Economics, 2002.
35. Herridge MS, Cheung AM, Tansey CM, et al. for the Canadian Critical Care Trials Group. One-year outcomes in survivors of the acute respiratory distress syndrome. New England Journal of Medicine 2003; 348: 683-93.
36. Critical Care Stakeholder Forum. Quality Critical Care. London: Department of Health, 2005.
37. Tukey JW. One degree of freedom for non-additivity. Biometrics 1949; 5: 232-42.
38. Pregibon D. Goodness of link tests for generalised linear models. Applied Statistics 1980; 29: 15-24.